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Abstract 
Background: Drug efficacy against kelch 13 mutant malaria parasites can be determined in vitro with the ring-stage 
survival assay (RSA). The conventional assay protocol reflects the exposure profile of dihydroartemisinin.
Methods: Taking into account that other anti-malarial peroxides, such as the synthetic ozonides OZ439 (artefenomel) 
and OZ609, have different pharmacokinetics, the RSA was adjusted to the concentration–time profile of these ozon-
ides in humans and a novel, semi-automated readout was introduced.
Results: When tested at clinically relevant parameters, it was shown that OZ439 and OZ609 are active against the 
Plasmodium falciparum clinical isolate Cam3.IR539T.
Conclusion: If the in vitro RSA does indeed predict the potency of compounds against parasites with increased toler-
ance to artemisinin and its derivatives, then the herein presented data suggest that following drug-pulses of at least 
48 h, OZ439 and OZ609 will be highly potent against kelch 13 mutant isolates, such as P. falciparum Cam3.IR539T.
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Background
Reduced in  vivo susceptibility of Plasmodium falcipa-
rum to semisynthetic artemisinin derivatives was first 
reported a decade ago in Cambodia, where patients 
displayed prolonged parasite clearance rates follow-
ing artesunate treatment [1, 2]. Since then, many more 
reports have confirmed those in  vivo findings [3], and 
the prolonged clearance rates were found to be associ-
ated with point mutations in the P. falciparum kelch 13 
gene [4, 5]. Activity against kelch 13 mutants is, therefore, 
a prerequisite for a new anti-malarial drug candidate. 
However, initially there was no in vitro susceptibility test 
that would pick up the increased tolerance to artemisinin 
derivatives [6]. This gap has been closed by Witkowski 
et  al. with the development of the so-called ring-stage 
survival assay (RSA) [7]. In the standard RSA, 0–3 h post-
invasion P. falciparum ring-stage parasites are incubated 
for 6  h at a dihydroartemisinin (DHA) concentration 
of 700  nM—conditions considered pharmacologically 
relevant.
Taking into account that other anti-malarial perox-
ides, such as the synthetic ozonide OZ439 (artefenomel), 
have different pharmacokinetic properties than the arte-
misinins [8], the aim of this study was to perform RSAs 
under clinically relevant conditions based on published 
concentration–time profiles of DHA and ozonides after 
single-dose treatment in clinical trials. The authors are 
aware that the single-dose scenario is not reflecting the 
standard anti-malarial treatment, where patients receive 
multiple dosings of artemisinins and in combination with 
a partner compound. The presented data should, there-
fore, be interpreted accordingly.
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Methods
Parasite cultivation
The artemisinin-resistant P. falciparum isolate Cam3.IR539T 
from Battambang, Cambodia was obtained from BEI 
Resources with the accession number MRA-1240. The 
corresponding revertant clone Cam3.Irev was kindly 
provided by David Fidock. Parasites were cultivated in 
standard culture medium, consisting of hypoxanthine 
(50  mg/l), RPMI (10.44  g/l) supplemented with HEPES 
(5.94 g/l), Albumax (5 g/l), sodium bicarbonate (2.1 g/l) 
and neomycin (100 mg/l) [9].
[3H]hypoxanthine incorporation assay
The in  vitro anti-malarial activities of compounds were 
measured using the modified  [3H]hypoxanthine incor-
poration assay [9]. Compounds were dissolved by 
sonication in DMSO (10 mg/ml) and diluted in hypoxan-
thine-free culture medium. Infected erythrocytes (100 μl 
per well with 2.5% haematocrit and 0.3% parasitaemia) 
were added to each drug titrated in 100  μl duplicates 
over a 64-fold range. After 48 h incubation, 0.25 microCi 
of  [3H]hypoxanthine in 50 μl culture medium was added 
and plates were incubated for an additional 24  h. Para-
sites were harvested onto glass-fiber filters and radioac-
tivity was counted using a Betaplate liquid scintillation 
counter (Wallac, Zurich). The results were recorded as 
counts per minute (cpm) per well at each drug concentra-
tion and expressed as a percentage of the untreated con-
trols. Fifty and ninety percent inhibitory concentrations 
(IC50 and IC90) were estimated by linear interpolation 
[10].
Ring‑stage survival assay
Using the ring-stage survival assay (RSA) adapted from 
Witkowski et al. [7], drug potency was measured against 
the Cambodian P. falciparum clinical isolate Cam3.I, 
which carries the kelch 13-propeller mutation R539T 
(Cam3.IR539T) and the corresponding revertant Cam3.Irev. 
Cam3.Irev is a Cambodian field isolate, in which the kelch 
13 mutation R539T was replaced with the reverted wild-
type allele [5]. In brief, parasites were synchronized to 
0–3 h post-invasion rings using 5% d-Sorbitol and a 75% 
Percoll cushion.
In the case of the conventional microscopic readout, 
0–3  h post-invasion rings (final haematocrit 1.8% and 
parasitaemia between 0.5 and 1%) were exposed to a drug 
pulse of 6 h in standard culture medium in 48-well plates 
(Corning, Cat. No. 3548). Then, the content of each well 
was transferred to a 1.5 ml Eppendorf tube and residual 
compound was removed by washing four times in 1  ml 
of standard culture medium, before the parasites were 
cultivated for another 66 h in the same medium in a new 
48-well plate. Afterwards, a thin blood smear was made 
from each well, parasitaemia was determined micro-
scopically by counting the number of parasitized cells in 
approximately 10,000 cells, and the survival rate was cal-
culated as percentage of the untreated controls.
In the case of the  [3H]hypoxanthine incorporation 
method, 0–3  h post-invasion rings (final haemato-
crit of 1.6% and parasitaemia between 0.1 and 1.2%) 
were exposed to a drug pulse of 6, 20 or 48 h in stand-
ard culture medium in 96-well plates (Sarstedt, Cat. No. 
83.3924). The content of all wells was then transferred to 
deep-well plates (Sigma-Aldrich, Cat. No. P8241-50EA) 
and compounds were removed through extensive wash-
ing with hypoxanthine-free culture medium (6 × 1  ml). 
The complete removal of compound after washing was 
verified by incubating the supernatant recovered after 
the last washing step with fresh cultures of NF54 (air-
port strain from The Netherlands, kindly provided by 
F. Hoffmann-La Roche Ltd) parasites for 72  h, ensuring 
that no growth inhibition was detected. After washing, 
drug-free parasites were re-incubated in hypoxanthine-
free medium for 22 h. Then, 0.5 microCi of  [3H]hypoxan-
thine in 50 μl of culture medium was added. Twenty-four 
hours after this  [3H]hypoxanthine incorporation period, 
the assay was terminated by freezing the plates at 
− 20  °C. The thawed plates were harvested using a Fil-
terMate Harvester (Perkin Elmer, Waltham, USA) and 
counts per minute (cpm) were obtained for each well by 
using the  MicroBeta2® 2450 Microplate Counter (Perkin 
Elmer, Waltham, USA). For each drug and concentra-
tion, the survival rate was calculated as percentage of the 
untreated controls. Three individual experiments were 
performed in technical duplicates.
Results
The minimal inhibitory concentration (MIC, defined as 
the concentration at which the parasite multiplication 
factor per asexual cycle equals one) is a critical concen-
tration determinant. Here, the in  vitro 90% inhibitory 
concentration (IC90) was used as proxy of the MIC, as 
recently proposed [11]. The inhibition curves of DHA, 
OZ277, OZ439 and OZ609 had previously been deter-
mined by the  [3H]hypoxanthine incorporation assay [9] 
against the P. falciparum strain Cam3.IR539T [12]. The 
mean IC90 values of DHA, OZ277, OZ439 and OZ609 
determined in two independent experiments were 6.0, 
4.3, 8.1, 5.1 nM, respectively (or 1.7, 1.7, 3.8 and 2.7 ng/
ml), and correlated with the data previously obtained 
with the sensitive strain NF54 in ≥ 3 independent 
experiments [12]. Using these experimentally deter-
mined IC90 values as a proxy for the MICs, the next 
step was to consult available concentration–time pro-
files from clinical trials performed with artesunate (the 
metabolic precursor of DHA) or synthetic ozonides. 
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DHA exposure profiles from two clinical trials in 
patients dosed orally with 4  mg/kg artesunate [13, 14] 
showed that plasma exposures above 700 nM (~ 200 ng/
ml) are achievable for about three hours (Additional 
file 1: Figure S1). Of note, 700 nM is the concentration 
chosen for the standard RSA [15], and corresponds to 
~ 115-fold the MIC (6.0 nM; see above).
Knowing that the maximal in  vitro killing rate of 
artemisinins [16] and ozonides (unpublished data on 
file with the Medicines for Malaria Venture) is reached 
at concentrations corresponding to about tenfold the 
IC50 (equivalent to fivefold the IC90/MIC, or ~ 10 ng/
ml), this rather low multiple of the MIC was applied to 
published concentration–time profiles of DHA. It was 
found that the fivefold multiple of the IC90/MIC can 
be maintained for a duration of ~ 6 h in patients (Addi-
tional file  1: Figure S1), which corresponds to the 6  h 
incubation time employed in the standard RSA. An 
additional concentration, which can be maintained for 
a duration of ~ 6 h in patients was found to be 25-fold 
the IC90/MIC, corresponding to ~ 40  ng/ml (Addi-
tional file 1: Figure S1). The same MIC multiples were 
also applied to published concentration–time profiles 
of the ozonides. From the exposure profile of OZ439 in 
patients dosed orally with 500 mg [17], it was estimated 
that 5- and 25-fold the IC90/MIC (~ 20 and ~ 100  ng/
ml) were achievable for 48 and 20  h, respectively 
(Additional file  1: Figure S1). For OZ277, no plasma 
concentration–time profile from infected patients is 
published. However, it is known that the activity of 
the synthetic ozonide OZ277 in clinical studies is in 
the same order of magnitude as that of the artemisinin 
derivative artemether in the artemether–lumefantrine 
combination [8]. Besides, the OZ277 plasma concen-
trations decline with a similar mean half-life range of 
2 to 4 h like DHA [18]. Thus, the same RSA parameters 
were chosen for OZ277 as for DHA (incubation at 5- 
and 25-fold the IC90/MIC for a duration of 6 h).
Up to now, OZ609 has not been tested in humans. 
However, the in  vivo half-life of OZ609 is predicted to 
be in the range of OZ439 (unpublished data on file with 
the Medicines for Malaria Venture). Hence, for OZ609, 
the same parameters were chosen as for OZ439 (incu-
bation at 5- and 25-fold the IC90/MIC for 48 and 20 h, 
respectively).
Having identified clinically relevant compound expo-
sure parameters, the original RSA described by Wit-
kowski et  al. [7] was adapted accordingly. Additionally, 
the drug washout was enhanced to ensure that no resi- 
dual peroxide was present during the post-treatment 
period [19]. Moreover, the RSA readout was made less 
subjective and laborious by replacing the microscopic 
readout with a semi-automated readout based on  [3H]
hypoxanthine incorporation (details are described in 
“Methods” section).
As a first step, the conventional microscopic readout 
was compared with the  [3H]hypoxanthine incorporation 
method by exposing the Cambodian isolate Cam3.IR539T 
for 6 h to 700 nM of DHA. Both readout methods pro-
vided a high survival rate of 20 to 24% (Fig. 1), which is 
comparable to the observed survival rates of 40%, 33% 
and 22% published previously [5, 12, 20].
Next, the percent survival of the same parasite isolate 
was determined after a 6 h exposure to 5- or 25-fold the 
IC90 (MIC) of DHA or OZ277 and compared with the 
percent survival of the genetically engineered wildtype 
strain Cam3.Irev. In line with previous observations [12, 
20] for both compounds, the clinical isolate Cam3.IR539T 
strain showed a higher survival than the sensitive Cam3.
Irev strain. The difference was most pronounced at 25-fold 
the IC90/MIC of both compounds (Fig. 2a).
When the two ozonides OZ439 and OZ609 were tested 
at their clinically relevant concentrations and exposure 
times (incubated at 5- and 25-fold the IC90/MIC for 48 
and 20  h, respectively), both compounds were highly 
active and showed close-to-equal potency against both 
strains (Fig. 2b).
Discussion
This article reports on experiments preformed with the 
synthetic compounds OZ277, OZ439 and OZ609 against 
a clinical isolate with a kelch 13 mutation and shows that, 
when tested at clinically relevant parameters, OZ439 and 
OZ609 are active against both the kelch 13 mutant as well 
as the wildtype revertant.
At the 48  h time point and with a range of OZ439 
concentrations, similar observations were also made 
by Yang et  al. [19]. This is also in line with reports 
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Fig. 1 Comparison of the mean survival ± standard deviation after 
DHA treatment, obtained from the  [3H]hypoxanthine incorporation 
method and the conventional microscopic readout with the 
Plasmodium falciparum clinical isolate Cam3.IR539T. In all assays, Cam3.
IR539T was exposed for 6 h to 700 nM of DHA. For both readouts, the 
mean values of n = 4 biological replicates are shown
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describing that mutations in the kelch 13 propeller gene 
did not have an impact on the median parasite clear-
ance half-life rate after treatment with OZ439 [21].
Conclusion
In conclusion, if the in  vitro RSA does indeed pre-
dict the potency of compounds against parasites with 
increased tolerance to artemisinin and its derivatives, 
then the herein presented data suggest that follow-
ing drug-pulses of at least 48  h, OZ439 and OZ609 
will be highly potent against kelch 13 mutant isolates 
such as P. falciparum Cam3.IR539T. This is consistent 
with modelling data [22] and recent trial data showing 
97.7% efficacy of a 6-day artemisinin-based combina-
tion treatment course [23]. Clearly, however, there is a 
need to constantly monitor the situation in the field by 
testing ozonides against additional clinical isolates and, 
importantly, at clinically relevant conditions.
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Additional file 1: Figure S1. Published plasma concentration–time pro-
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Fig. 2 Mean percent survival ± standard deviation of Plasmodium falciparum strains Cam3.IR539T and Cam3.Irev after exposure to DHA, OZ277, OZ439 
and OZ609 at clinically relevant compound exposure parameters. a Parasites were exposed for 6 h to 5- or 25-fold the IC90/MIC of DHA or OZ277 
(30 nM or 149 nM DHA; 15 nM or 74 nM OZ277). b Parasites were exposed for 20 h to 25-fold or 48 h to 5-fold IC90/MIC of OZ439 or OZ609 (168 nM 
or 34 nM OZ439; 96 nM or 19 nM OZ609). After drug removal, parasites were first incubated for 22 h with hypoxanthine-free medium, and then 
for 24 h with medium containing  [3H]hypoxanthine. After this  [3H]hypoxanthine incorporation period, the assays were terminated by freezing the 
plates at − 20 °C. At least three biological replicates were performed in each case
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